1.
Tran V-T, Harrington M, Montori VM, Barnes C, Wicks P, Ravaud P. Adaptation and validation
of the Treatment Burden Questionnaire (TBQ) in English using an internet platform.
BMC Med [Internet]. 2014 Dec 2 [cited 2018 Sep 4];12(1):109. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24989988
3.
May CR, Eton DT, Boehmer K, Gallacher K, Hunt K, Macdonald S, et al. Rethinking the
patient: using Burden of Treatment Theory to understand the changing dynamics of illness
[Internet]. Vol. 14. 2014 [cited 2018 Sep 4]. Available from: http://www.biomedcentral.com/1472-6963/14/281
4.
Tran V-T, Montori VM, Eton DT, Baruch D, Falissard B, Ravaud P. Development and description
of measurement properties of an instrument to assess treatment burden among patients
with multiple chronic conditions. BMC Med [Internet]. 2012 Dec 4 [cited 2018 Sep 4];10(1):68.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/22762722
5.
Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J, MSCOI Study Group the MS,
et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult
Scler [Internet]. 2017 Jul [cited 2019 Jan 16];23(8):1123–36. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28273775
6.
Gold R, Toumi M, Meesen B, Fogarty E. The payer’s perspective: What is the burden
of MS and how should the patient’s perspective be integrated in health technology
assessment conducted for taking decisions on access to care and treatment? Mult Scler
[Internet]. 2016 Aug 26 [cited 2019 Jan 16];22(2 Suppl):60–70. Available from: http://journals.sagepub.com/doi/10.1177/1352458516650743
7.
Kobelt G, Eriksson J, Phillips G, Berg J. The burden of multiple sclerosis 2015: Methods
of data collection, assessment and analysis of costs, quality of life and symptoms.
Mult Scler J [Internet]. 2017 Aug 23 [cited 2019 Jan 16];23(2_suppl):4–16. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/28643592
8.
Wicks P, Massagli M, Kulkarni A, Dastani H. Use of an online community to develop
patient-reported outcome instruments: the Multiple Sclerosis Treatment Adherence Questionnaire
(MS-TAQ). J Med Internet Res [Internet]. 2011 Jan 24 [cited 2019 Jan 17];13(1):e12.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/21266318
10.
U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research,
U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and
Research, U.S. Department of Health and Human Services FDA Center for Devices and
Radiological Health. Guidance for industry: patient-reported outcome measures: use
in medical product development to support labeling claims: draft guidance. Health
Qual Life Outcomes [Internet]. 2006 Oct 11 [cited 2019 Feb 15];4(1):79. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/17034633
11.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic
criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol
[Internet]. 2011 Feb [cited 2019 Jan 24];69(2):292–302. Available from: http://doi.wiley.com/10.1002/ana.22366
12.
Acquadro C, Conway K, Hareendran A, Aaronson N, European Regulatory Issues and Quality
of Life Assessment (ERIQA) Group. Literature Review of Methods to Translate Health-Related
Quality of Life Questionnaires for Use in Multinational Clinical Trials. Value Heal
[Internet]. 2008 May [cited 2019 Jan 10];11(3):509–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18179659
13.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability
status scale (EDSS). Neurology [Internet]. 1983 Nov [cited 2019 Feb 6];33(11):1444–52.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/6685237
14.
Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, et al. Development
of a multiple sclerosis functional composite as a clinical trial outcome measure.
Brain [Internet]. 1999 May [cited 2019 Feb 6];122 ( Pt 5):871–82. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/10355672
15.
Benedict RH, DeLuca J, Phillips G, LaRocca N, Hudson LD, Rudick R, et al. Validity
of the Symbol Digit Modalities Test as a cognition performance outcome measure for
multiple sclerosis. Mult Scler J [Internet]. 2017 Apr 16 [cited 2019 Feb 6];23(5):721–33.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/28206827
16.
Langdon DW, Amato MP, Boringa J, Brochet B, Foley F, Fredrikson S, et al. Recommendations
for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Mult
Scler [Internet]. 2012 Jun 21 [cited 2019 Feb 6];18(6):891–8. Available from: http://journals.sagepub.com/doi/10.1177/1352458511431076
17.
Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of
life measure for multiple sclerosis. Qual Life Res [Internet]. 1995 Jun [cited 2019
Feb 6];4(3):187–206. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7613530
18.
Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application
to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol
[Internet]. 1989 Oct [cited 2019 Feb 6];46(10):1121–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2803071
20.
BECK AT, WARD CH, MENDELSON M, MOCK J, ERBAUGH J. An inventory for measuring depression.
Arch Gen Psychiatry [Internet]. 1961 Jun [cited 2019 Feb 6];4:561–71. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/13688369
22.
Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported
measure of medication adherence. Med Care [Internet]. 1986 Jan [cited 2019 Feb 6];24(1):67–74.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/3945130
24.
Grupe DW, Nitschke JB. Uncertainty and anticipation in anxiety: an integrated neurobiological
and psychological perspective. Nat Rev Neurosci [Internet]. 2013 Jul [cited 2019 Jan
17];14(7):488–501. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23783199
26.
Manjaly Z-M, Harrison NA, Critchley HD, Do CT, Stefanics G, Wenderoth N, et al. Pathophysiological
and cognitive mechanisms of fatigue in multiple sclerosis. J Neurol Neurosurg Psychiatry
[Internet]. 2019 Jan 25 [cited 2019 Feb 17];jnnp-2018-320050. Available from: http://jnnp.bmj.com/lookup/doi/10.1136/jnnp-2018-320050
27.
Mateen FJ, Manalo NC, Grundy SJ, Houghton MA, Hotan GC, Erickson H, et al. Light therapy
for multiple sclerosis-associated fatigue. Medicine (Baltimore) [Internet]. 2017 Sep
[cited 2019 Feb 17];96(36):e8037. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28885372
29.
Ysrraelit MC, Fiol MP, Gaitán MI, Correale J. Quality of Life Assessment in Multiple
Sclerosis: Different Perception between Patients and Neurologists. Front Neurol [Internet].
2018 Jan 11 [cited 2019 Jan 23];8:729. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29375468
30.
Thach A V., Brown CM, Herrera V, Sasane R, Barner JC, Ford KC, et al. Associations
Between Treatment Satisfaction, Medication Beliefs, and Adherence to Disease-Modifying
Therapies in Patients with Multiple Sclerosis. Int J MS Care [Internet]. 2018 Dec
2 [cited 2019 Jan 22];20(6):251–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30568562
31.
Higuera L, Carlin CS, Anderson S. Adherence to Disease-Modifying Therapies for Multiple
Sclerosis. J Manag Care Spec Pharm [Internet]. 2016 Dec [cited 2019 Jan 22];22(12):1394–401.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/27882830
32.
Cohen BA, Coyle PK, Leist T, Oleen-Burkey MA, Schwartz M, Zwibel H. Therapy Optimization
in Multiple Sclerosis: A cohort study of therapy adherence and risk of relapse. Mult
Scler Relat Disord [Internet]. 2015 Jan [cited 2019 Jan 22];4(1):75–82. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/25787057
33.
Evans C, Marrie RA, Zhu F, Leung S, Lu X, Kingwell E, et al. Adherence to disease-modifying
therapies for multiple sclerosis and subsequent hospitalizations. Pharmacoepidemiol
Drug Saf [Internet]. 2017 Jun [cited 2019 Jan 22];26(6):702–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28370875
34.
Eton DT, Yost KJ, Lai J, Ridgeway JL, Egginton JS, Rosedahl JK, et al. Development
and validation of the Patient Experience with Treatment and Self-management (PETS):
a patient-reported measure of treatment burden. Qual Life Res [Internet]. 2017 Feb
26 [cited 2019 Jan 21];26(2):489–503. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27566732
35.
Mohammed MA, Moles RJ, Hilmer SN, Kouladjian O’Donnel L, Chen TF. Development and
validation of an instrument for measuring the burden of medicine on functioning and
well-being: the Medication-Related Burden Quality of Life (MRB-QoL) tool. BMJ Open
[Internet]. 2018 [cited 2019 Jan 20];8(1):e018880. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29330175
36.
Sav A, King MA, Whitty JA, Kendall E, McMillan SS, Kelly F, et al. Burden of treatment
for chronic illness: a concept analysis and review of the literature. Health Expect
[Internet]. 2015 Jun [cited 2019 Jan 19];18(3):312–24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23363080
37.
Sav A, Salehi A, Mair FS, McMillan SS. Measuring the burden of treatment for chronic
disease: implications of a scoping review of the literature. BMC Med Res Methodol
[Internet]. 2017 Sep 12 [cited 2019 Jan 15];17(1):140. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28899342
38.
Ridgeway JL, Egginton JS, Tiedje K, Linzer M, Boehm D, Poplau S, et al. Factors that
lessen the burden of treatment in complex patients with chronic conditions: a qualitative
study. Patient Prefer Adherence [Internet]. 2014 [cited 2018 Sep 4];8:339–51. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/24672228
40.
Boehmer KR, Kyriacou M, Behnken E, Branda M, Montori VM. Patient capacity for self-care
in the medical record of patients with chronic conditions: a mixed-methods retrospective
study. BMC Fam Pract [Internet]. 2018 Dec 2 [cited 2019 Feb 24];19(1):164. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/30285746
42.
Mohammed MA, Moles RJ, Chen TF. Medication-related burden and patients’ lived experience
with medicine: a systematic review and metasynthesis of qualitative studies. BMJ Open
[Internet]. 2016 Feb 2 [cited 2019 Jan 20];6(2):e010035. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26839015
43.
Spencer-Bonilla G, Quiñones AR, Montori VM, International Minimally Disruptive Medicine
Workgroup. Assessing the Burden of Treatment. J Gen Intern Med [Internet]. 2017 Oct
11 [cited 2018 Sep 4];32(10):1141–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28699060